137 related articles for article (PubMed ID: 37114359)
61. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
[TBL] [Abstract][Full Text] [Related]
62. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
63. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
[TBL] [Abstract][Full Text] [Related]
64. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
65. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
66. Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Lee JM; Moore RG; Ghamande S; Park MS; Diaz JP; Chapman J; Kendrick J; Slomovitz BM; Tewari KS; Lowe ES; Milenkova T; Kumar S; Dymond M; Brown J; Liu JF
Clin Cancer Res; 2022 Oct; 28(19):4186-4193. PubMed ID: 35917514
[TBL] [Abstract][Full Text] [Related]
67. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
[No Abstract] [Full Text] [Related]
68. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Hardesty MM; Krivak TC; Wright GS; Hamilton E; Fleming EL; Belotte J; Keeton EK; Wang P; Gupta D; Clements A; Gray HJ; Konecny GE; Moore RG; Richardson DL
Gynecol Oncol; 2022 Aug; 166(2):219-229. PubMed ID: 35690498
[TBL] [Abstract][Full Text] [Related]
69. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X
J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885
[TBL] [Abstract][Full Text] [Related]
70. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Hjortkjær M; Kanstrup H; Jakobsen A; Steffensen KD
Cancer Treat Res Commun; 2018; 14():7-12. PubMed ID: 30104007
[No Abstract] [Full Text] [Related]
71. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
72. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
[TBL] [Abstract][Full Text] [Related]
73. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
74. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
75. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
76. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
77. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract][Full Text] [Related]
78. Niraparib: First Global Approval.
Scott LJ
Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
[TBL] [Abstract][Full Text] [Related]
79. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract][Full Text] [Related]
80. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
Cao Y; Chen H; Huang Y; Hu H
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1180. PubMed ID: 32721133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
